RESEARCH: RIPK1-VHL-INTERACTION
FOLDING PROJECT #16770 PROFILE

This project looks at how two proteins, RIPK1 and VHL, interact with each other. Understanding their interactions could help create new drugs that target specific diseases.

This project is going to investigate the protein-protein interaction between ripk1 and E3 ligase vhl.

Examing the appropriate metastable states will facilitate the design of PROTAC.

RIPK1

Receptor-interacting protein kinase 1

RIPK1 is a protein kinase involved in cellular processes like apoptosis and inflammation. Its dysregulation can contribute to various diseases, making it a target for drug development.

E3 Ligase

A type of enzyme that facilitates the attachment of ubiquitin to target proteins.

E3 ligases play a crucial role in protein degradation and signal transduction pathways. They recognize specific target proteins and recruit E2 enzymes to attach ubiquitin molecules, marking them for degradation.

VHL

Von Hippel-Lindau tumor suppressor protein

VHL is a tumor suppressor protein that regulates cell growth and oxygen sensing. Mutations in VHL can lead to the development of various cancers.

PROTAC

Proteolysis targeting chimera

PROTACs are a novel class of drugs that leverage the ubiquitin-proteasome system to degrade specific target proteins. They consist of two parts: a ligand that binds to the target protein and a PROTAC recruiter that interacts with an E3 ligase.